Skip to content

Functional Status and Quality of Life in Older Patients Undergoing Robotic Surgery for Colorectal Cancer

Prospective Evaluation of Functional Status and Quality of Life in Older Patients With Colorectal Cancer Undergoing Robotic Surgery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05848609
Acronym
ROBO-G
Enrollment
120
Registered
2023-05-08
Start date
2023-03-15
Completion date
2026-12-31
Last updated
2023-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Surgery, Geriatric Assessment, Quality of Life

Brief summary

The present study evaluates prospectively the impact of robotic surgery on functional outcome and quality of life in older patients that are operated for colorectal cancer;

Interventions

DIAGNOSTIC_TESTGeriatric Assessment

Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery

Sponsors

Universitair Ziekenhuis Brussel
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients ≥ 70 years with colorectal cancer * eligible for colorectal surgery after multidisciplinary board evaluation and patient consent

Exclusion criteria

* decline in cognitive function after geriatric evaluation * emergency surgery * life expectancy \< 3 months

Design outcomes

Primary

MeasureTime frameDescription
Change in frailty status GFI statusBefore and 3-6-12 months after surgeryMeasurement of functional status using the Groningen Frailty Indicator (GFI) Screening Tool (fTRST)
Change in Quality of LifeBefore and 3-6-12 months after surgeryMeasurement of QoL using validated EORTC QoL questionnaire
Change in frailty status G8 statusBefore and 3-6-12 months after surgeryMeasurement of functional status using the G8, Flemish version of the Triage Risk Screening Tool (fTRST)

Secondary

MeasureTime frameDescription
Percentage of patients demonstrating a significant decrease/improvement of QoL at 3,6,12 months after surgery3-6-12 months after surgeryPercentage of patients demonstrating a significant decrease/improvement of QoL at 3,6,12 months after surgery
Conversion-rate to open surgeryduring surgeryNumber of patients where surgery can not be completed minimal invasive
Length of hospital stayImmediate after surgeryTime patient spends in hospital
Re-operation and re-admission rate< 30 days after surgeryneed for re-intervention or hospitalisation after discharge
Evolution of post-operative cognition3, 6, 12 months post surgeryMini-cog clock test followed by Mini Mental State Evaluation (MMSE) if abnormal
30- day post-operative morbidity (Clavien-Dindo classification)< 30 days postoperativeminor and major postoperative complications including anastomotic leakage
90- day post-operative mortality< 90 days postoperativenumber of patients that die after surgery
1-year patient survival1 year postoperativelynumber of patients that are still alive one year after surgery
1-year disease free survival1 year postoperativelynumber of patients that do not show disease recurrence during the first postoperative year
Comparison in outcome parameters between frail patients (abnormal screening) versus fit patientsup till 12 months postoperativelyComparison in outcome parameters between frail patients (Groningen frailty indicator ≥ 4) versus fit patients (frailty indicator \< 4)
Postoperative confusion rate7 days postoperativeCAM-analysis
Percentage (%) of patients demonstrating functional improvement at 3, 6 and 12 months after surgery3-6-12 months after surgeryPercentage (%) of patients demonstrating functional decline/improvement at 3, 6 and 12 months after surgery
Percentage of patients demonstrating functional recovery at 12 months after initial func-tional decline after surgery3-6-12 months after surgeryPercentage of patients demonstrating functional recovery at 12 months after initial func-tional decline after surgery

Other

MeasureTime frameDescription
pathological analysis resection specimenimmediately after surgerytumor stage, lymph node yield, resection quality
blood lossduring surgeryestimated blood loss during surgery

Countries

Belgium

Contacts

Primary ContactEllen Van Eetvelde, MD
ellen.vaneetvelde@uzbrussel.be+324775656
Backup ContactDaniel Jacobs-Tulleneers-Thevissen, MD, PhD
daniel.jacobs-tulleneers-thevissen@uzbrussel.be+324775656

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026